Syneron Medical Hits Estimates in Solid Quarter
Syneron Medical (NAS: ELOS) reported earnings on May 22. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Syneron Medical met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share expanded. GAAP loss per share was unchanged.
Margins grew across the board.
Syneron Medical reported revenue of $61.2 million. The four analysts polled by S&P Capital IQ wanted to see sales of $61.2 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.02. The four earnings estimates compiled by S&P Capital IQ predicted $0.02 per share. Non-GAAP EPS were $0.02 for Q1 compared to -$0.05 per share for the prior-year quarter. GAAP EPS of -$0.07 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 53.0%, 160 basis points better than the prior-year quarter. Operating margin was -4.2%, 60 basis points better than the prior-year quarter. Net margin was -4.0%, 20 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $74.9 million. On the bottom line, the average EPS estimate is $0.12.
Next year's average estimate for revenue is $289.9 million. The average EPS estimate is $0.47.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 700 members out of 732 rating the stock outperform, and 32 members rating it underperform. Among 176 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 171 give Syneron Medical a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is buy, with an average price target of $16.50.
Is Syneron Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Syneron Medical to My Watchlist.
The article Syneron Medical Hits Estimates in Solid Quarter originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.